Saturday 17 October 2026
Export EDSA’s income statement to Excel — free account
Edesa Biotech, Inc.
EDSA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 140.0% and free cash flow fell 81.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.57
0.10
−3.75%
Follow EDSA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (531.32%) | (255.48%) | (263.19%) | (277.81%) |
+8 more TTM periods Free account |
|
| (102.46%) | (72.43%) | (82.82%) | (82.86%) | ||
ROIC |
0.00% | (3,564.31%) | (274.45%) | (297.91%) | |
Return on Tangible Assets |
(205.26%) | (126.90%) | (65.34%) | (68.86%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.99) | (0.88) | (0.99) | (1.29) | |
Free Cash Flow |
(8.91) | (7.53) | (7.89) | (7.32) | |
| Other line items | |||||
Cash ROIC |
(46.53%) | (37.26%) | (30.35%) | (31.50%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.63 | 0.72 | 1.01 | 1.02 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.99) | (0.88) | (0.99) | (1.29) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates